ESG Tracker
  • Companies
  • Rankings
  • Portfolios
  • My Portfolios
  • Log In Log Out
  • Contact

← Back to search

MYRIAD GENETICS, INC.

MYGN · NASDAQ

Pharmaceutical Preparation Manufacturing · US

Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.

ESG Overview

Overall: BBB (High)
E: BBS: BBG: B

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $5.12 +0.31 (+6.44%)
Market Cap$479M
P/E Ratio—
EPS$—
52W High$11.44
52W Low$3.76
Beta1.94

Data from Finnhub · Updated Mar 11, 2026

Products and Services
  • Company Search
  • Rankings
  • Portfolios
About ESG Tracker
  • FAQ
Legal & Security
  • Disclosures
  • Privacy Policy
Contact
  • Contact Us
ESG Tracker

ESG Tracker is for informational purposes only and does not constitute investment advice. The operator of this site is not a registered investment advisor. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.

Public ESG data sourced from Public Company ESG Ratings Dataset by esgcompare.org, licensed under CC BY-NC-SA 4.0. This site is non-commercial and for informational purposes only.